Mnemo Therapeutics
Christine Foster, DPhil, is Chief Business Officer at Mnemo. An accomplished business leader with a strong scientific background, Christine has more than 30 years of industry experience in both biotechnology companies and large pharmaceutical organizations. Christine developed and executed strategic partnerships in the transformative field of genome editing with Intellia Therapeutics and Metagenomi Therapeutics where she guided acquisitions; played a critical role in the execution of deals with Affini-T Therapeutics, Ionis Pharmaceuticals, Regeneron Pharmaceuticals, and Novartis; and established novel co-development and co-commercialization relationships with Onk Therapeutics, SparingVision, Kyverna Therapeutics, and Avencell. She has led business development, alliance management, and corporate development activities through key phases of growth at Acceleron Pharma, Sunovion Pharmaceuticals, Inc., Teva Pharmaceuticals, Wyeth (now Pfizer), and GlaxoSmithKline, among others. Trained as a scientist, Christine earned a D.Phil. in pharmacology from the University of Oxford and completed post-doctoral fellowships at Brandeis University in neuroscience and the University of Massachusetts Medical School in cardiovascular diseases.
This person is not in any teams
This person is not in any offices
Mnemo Therapeutics
1 followers
Mnemo Therapeutics is a biotechnology company focused on developing powerful cell therapies that create accessible cures for solid tumors and blood cancers. Its EnfiniT platform, a groundbreaking drug discovery engine, leverages a new class of antigens with greater tumor specificity and a suite of technologies to significantly improve T cell memory, persistence, and sensitivity. The result is dramatic improvement in the body’s immune response to overcome disease. Mnemo is built by a transatlantic team of scientists and biotech leaders united in their mission to create the most powerful immune therapies to deliver accessible cures for all patients in need.